Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF
Clinical trial NCT03071055 · COMPLETED
Trial details
- NCT number
- NCT03071055
- Sponsor
- Southeast Clinical Research Associates, LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-10-01
- Primary completion
- 2019-06-03
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.